Petro Matad CEO Mike Buck confirmed that he believes the Exploitation Licence for Block XX in Eastern Mongolia is likely to be awarded in Q2. Watch the full video here.
Thanks Starvest 14p bid would be excellent, each 10% rise should add 0.06 to the SP of KIBO
Current market cap £11.9m
MAST as of IPO £12.9m (55%)
Katoro Gold 29.9% £2m
As of 8am cash equivalents of ~£15m vs a market cap at 0.50 of £11.9m
Current assets/projects internal being given zero value
Some potentially good news IF we are manufacturer
Halifax, Nova Scotia--(Newsfile Corp. - April 12, 2021) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona"), a developer of rapid, point-of-care diagnostic tests is pleased to announce that it has been granted Health Canada Investigational Testing Authorization for a clinical trial of the Sona Saliva C-19 Rapid Test, a saliva sample-based rapid COVID-19 antigen test, with the Humber River Hospital in Toronto. The trial is expected to commence shortly, following final ethics review board sign-off of the trial protocol amendments required by Health Canada. The trial's objective is to determine the clinical performance of the test when compared to RT-PCR, in symptomatic patients. Analytical validation studies would also be required to support any regulatory submissions.
David Regan, CEO, comments, "New, less invasive rapid tests are needed to support frequent testing and a test that works with saliva would make regular testing for everyone much more accessible and tolerable. Developing a rapid antigen test for COVID-19 that works with saliva is complex, as evidenced by the absence of any FDA or Health Canada approved saliva sample-based rapid COVID-19 antigen tests. Sona has invested several months in the laboratory to adapt and optimize the performance of its test to enable it to work with saliva samples and we look forward to working with the Humber River Hospital on this trial of our saliva test."
*** In other news ***
Avacta have announced results 22nd April so hopefully they anticipate a CE mark before this date (not sure how you can time that) but be nice to get a test out there by month end
Not sure I underatand the debate here
Existing Projects (Benga etc.) Valued at ?
MED IPO £12.95m providing no change
KAT (Katoro Gold 29.9% stake) ~£2m
Warrants / Cash etc. etc. You are looking at, at least £15m MCAP
Yep people sold today under 0.46p which is ~£10.5m MCAP
Is there more to it, or are we still ~40% minimum under fair value pre-IPO?
Lots of great buys coming in the last 2 days, 25k blocks yesterday, a 40k one earlier and now multiple 30k blocks, someone definitely loading up a six figure position
Bodes well, not sure where the stock is coming from but hopefully this person knows something positive!
Unsure if it is algorithms that calculate and action the spread, or if it is human interaction, if it is the latter then whoever is running the show here must be driving a bentley to work every day because I dont think the spread has been less than 5% for a period of more than a couple of minutes in the last 3-4 months
Tuned in for the presentation today
Unfortunately no commercial or business Q's were asked in the Q+A as it was not intended for that, but more about how antibody testing is vital to study the development and progression of the virus, and the effectiveness of the vaccines on various strains
Some very interesting points raised, they did a study in Ireland with about 1500 participants, and got them to rate how easy the test was to use (self testing) - the score came back at 96%, suggesting just that, 96% of users will not struggle to use this test and interpret the result if it had to be self administered, a top result
They also shown the data to back up the sensitivity of 97.6% and Spec of 99.6% (may be higher off the top of my head) pretty solid compared to other tests
Such a detailed presentation, everyone presented very well, extremely educational, unfortunately there are so many Q's to answer about where the virus may go, how it may mutate, what vaccines are effective at what rates, how long antibodies last, the effectiveness of one dose vs two doses at different intervals, whether you have had CV19 or not etc.!
Back to our investment and potential commercials, one slide did stand out the most to me, and that was the AppDX software, which can be easily rolled out with the test and used as a vaccine passport (they specifically used the word vaccine passport) which I thought bodes very well for the tender
We certainly have a lot to offer, a very easy to use ABC19 Antibody test that detects IgG which is what you want, and secondly software/app to go with it so results can easily be recorded and vaccine passports (if issues) can be presented
I honestly dont know how we can roll out these vaccines without at least gaining some data on the effectiveness of them in the field
Unfortunately the data showed that upto 6 weeks post first vaccination, only around 70-80% of people have neutralising antibodies, after a second dose that number went up to 99% which is fantastic of course, but still 1 in a 100 may not have neutralising antibodies even post double dose vaccination, so I can see the need for antibody tests to be rolled out at some point over the next couple of Q's
the IPO was intended to raise £5m and they raised in excess of £5m (£5.5m if I am correct), after costs that equates to around £4.7m
You can read all the details here, I will post some of the interesting parts
The Net Placing Proceeds of £4,745,000, being the £5,540,000 Gross Placing Proceeds less the £795,000 Cash-Settled Transaction
Costs, will be used to fund:
• capital expenditure to further develop the Bordersley Project under a joint development agreement with AB Impianti S.R.L,
including constructure of the reserve power plant and infastructure required for the site to be operational - £1,140,000;
• Project 2 (9MW in Alferton Derbyshire) cash acquisition costs, including cash consideration, associated costs and expenses
for the acquisition if and when binding terms are entered into - £1,500,000;
• Project 3 (6MW in West Midlands) cash acquisition costs, including cash consideration, associated costs and expenses for
the acquisition if and when binding terms are entered into - £180,000; and
• operating costs of the Group - £1,925,000
Personally I would be happy if it just held 12.5p until the projects develop, that would still equate to 0.6p+ for KIBO
Any 10% rise would be ~0.06p to the share price, so a 20% rise and hold on the day could see us valued at 0.7p+
Complete speculation, but personally I would rather be buying KIBO that MAST as of right now as you are in theory getting IPO shares (55% exposure) for ~£10 MCAP (minus our KAT investment) £8m MCAP
Bought in on Monday at 0.36p
Looks absolutely solid this barring any market forces we cannot control like a stupid fundraise (when in reality absolutely no requirement to)
KAT (Katoro) holding worth £2m
MED IPO should give us £12.5m (or therabouts)
£14.5m MCAP 45% upside from here would be ~0.6p
Any increase in MED on IPO, each 10% rise adds £1.25m or 0.06p to the market cap POST IPO
Love these plays, did well on BRH pre-dividend (should have made so much more!) and quite well on FFWD from 8p all the way to 15p (thats now back to 8p but I am looking to trade that again to around 11-12p)
80% confident we will see 0.6p in the next couple of weeks, 90% confident we will see 0.55p
Long time no post
£17m MCAP now at 8p
Didn't expect much movement last couple of weeks, and dont expect much first week of April but I do think we will get some deals over the line come end of April, sitting on what I estimate to be a large cash position of around £7m / £7.5m at the moment
Shame as now would probably be a good time to do some deals, with the market on a downturn
My current fair value for the PF is around 11p
This of course uses valuations for Leap, Juve and Vemo as of 30th September 2020, it's up to you to decide whether or not they have increased/decreased in valuation since
A lot of people believe Leap is worth a lot more, I remain humble as again, 11p is nice upside from 8p - so happy to hold and will look to add more here as long as we stay below 10p
Catalysts that could send the SP higher
Revaluation of the PF showing NAV art £23m+
Increase in valuation for Leap (£7.3m currently)
Further investments or increasing stake
IPO's / Listings, as long as it's not the CSE :-)
Emmac sale has clearly put a lot of people off, but you can't argue with NAV so it is what it is, the upside may or may not be limited but I still think we will see 11p+ in Q2 minimum - I also think the downside is very limited here but you never know what the market will do
Great news Bozi
I have added more, that’s my lot, so I can take some out on the way up and not feel bad or like I’ve missed the boat
Key for me, is this is being used as a home self test, which before today was not allowed, odd that it can be used like that via Biobank for research but not sold, let’s see, will we get MHRA approval now?
Not missing anything Muck, the company is very quiet (albeit very professional IMHO)
-AVCT tie up, with their CE marking expected this week
// we have been working with Avacta for over 9 months, if the CE mark data reflects the initial early data from Europe (56 sample) we will be a very busy lucrative company
-More manufacturing capacity than ODX, but half its MCAP
/// Correct (I hold ODX simply because I like the sector, and they have a very good contact, plus 8m can easily become 12m+ in due course) We are targetting 150m PA by Y/E 2021 with a presence in the US
-1m unit sale of PCRD to a customer going through eua process for its Ag test, so potential for much more. Based on c£150 for 50 units, that’s a £3m order. Not insignificant, and surely to a larger player?
/// I've gone more for ~£2m here, that price is discounted when you order 10 boxes or more (each box contains 50 tests) therefore I assumed that for a large 1m order, they would probably get around £100 a box (1m/50 = 20K x £100)
-ABC19 stockpiled, more talk of its use, and CK very recently saying there is an exciting opportunity for it.
Increased recruitment, warehousing etc in the last 2 weeks
/// also stockpiled by Omega, if you check twitter, seven tier 1 orders pending approval in various countries, and 30+ countries in the pipeline pending approval, I had written this off but it could easily help us surpass our current market cap alone
Low free float and II lock ins
/// Yep locked in for 6-12 months I believe? Which begs the question who is selling the 10K blocks down here?
Other Ag manufacturing agreements
/// One is like a canadian company (I won't mention the name) the other TT signed in Jan/Feb is interesting which a UK company, and we know the final one is with Avacta (not sure if we have one more?) to go on top of the PCRD units, the APPDX software and the ABC19 test (a lot of people forget about the patented APPDX software)
-Heavily promoted webinar next week, to detail the benefit of Abc19 with vaccine roll out
/// Look forward to it
-Stuttering vaccine roll outs across the world
- on track with FDA approval and registrations with 30 other countries for Abc19
/// Sorry got to the bottom and noticed you already pointed this out!
Great post! and in summary, yes I am confused too but I dont think we are missing anything, I think the market is just overlooking it - for what reason, I am not sure, could be because most of the focus was on the ABC19 test, but I expect sentiment to turn very quickly here and when it does it will motor very fast, I am expecting multiple 10%+ back to back days at some point next month
Good find AJ
It also states that 500K tests were donated to BioBank by DHSC
Also, they used a different test but are now using the ABC test? I was thinking this may refer to Feb / March 2020 but then realised that CV19 had not hit the UK and therefore there would be no antibody testing, so must refer to this year - very interesting indeed, if the test is being used as home use, may we finally see home / self testing approval?
In order to start the study as quickly as possible, we used the Fortress Fast COVID-19 Device in phase 1 of the study (which took place February-March) as this device has been used in other research studies and we were able to obtain rapid regulatory approval for its use in UK Biobank. The AbC-19 Rapid TM kit being used in phase 2 (the current phase of the study) took longer to obtain the necessary approvals for use. Both kits can detect whether you have antibodies to the SARS-CoV-2 virus.